Annual Report

Investors and patients await Puma Bio's Q4 results, focusing on NERLYNX sales performance and crucial updates on its promising alisertib cancer pipeline.

The Midwest bank saw record earnings and shareholder returns in 2025, but a rise in nonperforming loans adds a layer of complexity to its growth story.

Investors eye Globus Medical's upcoming report for a full-year look at its NuVasive integration, market trends, and a pivotal 2025 performance.

The streaming pioneer smashed Q4 estimates and returned to full-year profitability, signaling a strong 2026 with ambitious growth targets for its ad platform.

Restaurant Brands International reports strong 2025 results, fueled by booming international sales, but faces headwinds with Popeyes' slump and BK franchisee pressures.

The newly rebranded firm touts record fundraising and a key acquisition, but declining non-GAAP earnings reveal a more complicated financial reality for investors.

With its Q4 and full-year 2025 earnings release imminent, Ingevity faces investor scrutiny over its recent strategic divestitures and market position.

Amid a surging aerospace market, StandardAero's upcoming earnings report is highly anticipated after a year of record growth and strategic expansion.

Terex declared a steady dividend, but the real story is its surging stock and a bold forecast, revealing deep confidence in its strategic direction.

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

Activist investor Impactive Capital nominates four directors to the WEX board, citing years of underperformance and demanding a strategic overhaul.

The private jet operator posted record revenue with fewer planes, achieving its first-ever quarter of positive Adjusted EBITDA in a major turnaround.

The French mining giant is in a full-blown leadership crisis, with its CFO suspended amid an employee-triggered probe just days after its CEO was fired.

As HUTCHMED prepares to unveil its 2025 financials, investors weigh a complex picture of global drug success, domestic pressures, and pipeline promise.

As Amwell prepares its 2025 results, investors watch to see if its strategic pivot to profitability can redefine the future of digital healthcare.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

In a volatile market, NASIS founder Karen Kennedy shares a crisis-forged blueprint for disciplined investing and avoiding the perils of herd mentality.

New 2025 data shows contractors using platforms like ServiceTrade cut emergency calls 27% and boost margins, proving the ROI of a data-driven model.

Sila Realty Trust sets its 2025 earnings date. Investors are watching to see if its strategic acquisitions and dividend policy signal strength for the sector.

Life sciences giant QIAGEN defies economic headwinds with strong 2025 results, signaling aggressive growth in single-cell analysis and bioinformatics.